Analyst Price Targets — XERS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 9:28 pm | — | Barclays | $9.00 | $6.99 | TheFly | Xeris Biopharma initiated with an Overweight at Barclays |
| October 29, 2025 12:14 pm | Leland Gershell | Oppenheimer | $18.00 | $9.97 | TheFly | Xeris Biopharma price target raised to $18 from $8 at Oppenheimer |
| March 7, 2025 12:02 pm | — | Piper Sandler | $4.00 | $4.24 | TheFly | Xeris Biopharma price target raised to $4 from $3 at Piper Sandler |
| November 11, 2024 12:23 pm | Oren Livnat | H.C. Wainwright | $6.60 | $3.25 | StreetInsider | Xeris Pharmaceuticals (XERS) PT Raised to $6.60 at H.C. Wainwright |
| October 23, 2024 6:18 am | Leland Gershell | Oppenheimer | $5.00 | $3.02 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS) |
| May 10, 2024 8:29 am | David Amsellem | Piper Sandler | $3.00 | $1.85 | StreetInsider | Xeris Pharmaceuticals (XERS) PT Lowered to $3 at Piper Sandler |
| April 28, 2022 9:49 am | — | Craig-Hallum | $6.50 | $2.33 | Benzinga | Craig-Hallum Initiates Coverage On Xeris Biopharma Holdings with Buy Rating, Announces Price Target of $6.5 |
Latest News for XERS
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.03 per share a year ago.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris…
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XERS.
U.S. House Trading
No House trades found for XERS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.